Ophthalmic Immunomodulators – lifitegrast 5% ophthalmic solution (Xiidra™)

WA.PHAR.58 Ophthalmic Immunomodulators- Lifitegrast 5% Ophthalmic Solution

Effective: October 1, 2018

Medical necessity

Drug	Medical Necessity
lifitegrast 5% ophthalmic solution (**Xiidra**™)	Xiidra™ may be considered medically necessary when prescribed for a dry eye disease

Clinical policy:

Clinical Criteria	
Initial Authorization Criteria	1. Diagnosis of moderate to severe chronic dry eye disease (DED) 2. Documentation is provided indicating an abnormal result or response to one or more of the following dry eye disease diagnostic/assessment methods: a. Tear break-up time (less than 10 seconds) b. Ocular surface dye staining using fluorescein, rose bengal, or lissamine green dyes c. Schirmer test (aqueous tear production of less than or equal to 10 mm of strip wetting in 5 minutes) d. Fluorescein clearance test/tear function index e. Tear osmolarity (indicating tear film instability) f. Tear lactoferrin concentrations in the lacrimal gland (decreased) 3. History of failure, contraindication or clinically significant intolerance to cyclosporine 0.05% ophthalmic emulsion (RESTASIS®) for at least 28-days 4. Greater than or equal to (≥) 17 years of age 5. Not used concomitantly with cyclosporine 0.05% ophthalmic emulsion (RESTASIS®) 6. Dose does not exceed 2 drops per day in each eye 7. Prescribed by or in consultation with a specialist in eye care or rheumatology **Approve for 6 months**
Reauthorization Criteria	1. Documentation of clinically significant improvement

	2. Continues to not use concomitantly with cyclosporine 0.05% ophthalmic emulsion (RESTASIS®) 3. Dose does not exceed 2 drops per day in each eye **Approve for 6 months**

Dosage and quantity limits

Drug Name	Dose and Quantity Limits
lifitegrast 5% ophthalmic solution (**XIIDRA™**)	One drop in each eye twice daily; #60 single-use vials per 30-days

References

1. Product Information: XIIDRA® topical ophthalmic solution, lifitegrast 5% topical ophthalmic solution. Shire US Inc (per FDA), Lexington, MA, 2017.
2. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. *Ophthalmology.* 2004 Mar;111(3):476-82.
3. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Dry Eye Syndrome. American Academy of Ophthalmology; 2013. URL: www.aao.org/ppp. Available from Internet. Accessed 2016 July.
4. Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. *Br J Ophthalmol*. 2010 Oct;94(10):1312-5.
5. Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. *Arch Ophthalmol*. 2009 Feb;127(2):146-52.
6. Mah F., et al. PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. *Clin Ophthalmol.* 2012;6:1971-6.
7. National Eye Institute. Facts About Dry Eye. National Institutes of Health. February 2013. URL: https://nei.nih.gov/health/dryeye/dryeye. Available from Internet. Accessed 2016 July.
8. Ocular Lubricants. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2012. Available from Wolters Kluwer Health, Inc. Accessed 2016 May 16.
9. Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. *Ann Allergy Asthma Immunol*. 2002 Sep;89(3):298-303.
10. Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006 Jan;32(1):21-6.
11. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000 Apr;107(4):631-9.
12. Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebocontrolled study of novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Opthalmol. 2012;153(6):1050-60.
13. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of DED: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475-83.
14. Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423-31.
15. Xiidra (lifitegrast) [package insert]. Lexington, MA: Shire US Inc.; July 2016.